No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

10/6

Chiesi group

Arbor

Biotechnologies

ABO-101

GOX inhibitors

Metabolic disorder

Primary hyperoxaluria type 1

Phase 1/2

2,115

2

10/6

AstraZeneca

Algen

Biotechnologies

AlgenBrain™

AI-driven functional

genomics platform

Immunology

-

-

555

3

10/8

Zenas BioPharma

InnoCare Pharma

Orelabrutinib
Obexelimab

BTK inhibitor

CD19 x FcγRIIb BsAbs

Immunology

Immunology

Multiple sclerosis

IgG4-RD

Phase 3

Phase 3

2,000

4

10/10

Chugai

Pharmaceutical

Roche

CT-388

GLP-1R x GIPR dual

modulator

Metabolic disorder

Obesity, T2D

Phase 2

n/d

5

10/14

Takeda

Nabla Bio

JAM
(Joint Atomic
 Model)

AI protein design platform

-

-

-

1,000

6

10/15

Boehringer

Ingelheim

Aimed Bio

n/d

ADC

Oncology

n/d

n/d

991

7

10/15

Novo nordisk

Omeros

Zaltenibart
(OMS906)

MASP-3 inhibitor

Hematology

paroxysmal nocturnal

hemoglobinuria (PNH)

Phase 2

2,100

8

10/16

Dianthus

Therapeutics

Nanjing Leads
 Biolabs

DNTH212
(LBL-047)

Bifunctional BDCA2 and

BAFF/APRIL inhibitor

Immunology

Autoimmune disease;

Sjögren's syndrome,

SLE,

Dermatomyositis,

Hidradenitis suppurativa,

Scleroderma,

Pemphigus vulgaris

Phase 1

1,000

9

10/17

Roche

Hansoh Pharma

HS-20110

CDH17 ADC

Oncology

Colorectal cancer

Phase 1

1,450

10

10/20

Lundbeck

Contera Pharma

AttackPoint

Discovery®,

OligoDisc®,

SpliceMatrix®

RNA discovery platforms

Neurology

Brain diseases

n/d

n/d

11

10/21

Samsung Bioepis

Phrontline

Biopharma

TJ108

EGFR x HER3 Bispecific,

dual-payload ADC

Oncology

Solid tumors; NSCLC

Preclinical

n/d

12

10/21

Takeda

Innovent

Biologics

IBI363

IBI343

IBI3001

PD-1 x IL-2Rα BsAbs

CLDN18.2 ADC

EGFR x B7-H3 Bispecific

ADC

Oncology

Oncology

Oncology

sqNSCLC; MSS CRC

Gastric cancer, Pancreatic cancer

Advanced or metastatic solid

tumor

Phase 2

Phase 3

Phase 1

11,400

13

10/24

Biogen

Vanqua Bio

n/d

C5aR1 antagonist

Immunology

Neutrophil-mediated inflammation

Preclinical

1,060

14

10/27

GSK

Syndivia

n/d

ADC

Oncology

mCPRC

Preclinical

357

15

10/28

GSK

Empirico

EMP-012

GaINAc-conjugated siRNA

Immunology

COPD

Phase 1

745

16

10/29

Regeneron

Pharmaceuticals

ModeX

Therapeutics

MSTAR Platform

Generating multispecific

antibodies platform

Immunology,

Oncology,

Metabolic disorder

n/d

-

1,007

17

10/29

Everest Medicines

Visera
(NovaBridge)

VIS-101

VEGF-A x ANG2 BsAbs

Ophthalmology

wAMD, DME, RVO

Phase 2

96

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

10/9

Novo Nordisk

Akero Therapeutics

Efruxifermin

FGF21 agonist

Metabolic disorder

MASH

Phase 3

5,200

2

10/10

BMS

Orbital Therapeutics

OTX-201

CD19 CAR-T

Immunology

Autoimmune disease

Preclinical

1,500

3

10/14

BioCryst

Pharmaceuticals

Asteria Therapeutics

Takhzyro

αKLKB1 mAb

Immunology

Hereditary angioedema (HAE)

Marketed

700

4

10/22

Ipsen

ImCheck Therapeutics

ICT01

αBTN3A mAb

Oncology

AML

Phase 1/2

1,160

5

10/22

Alkermes

Avadel Pharmaceuticals

Lumryz

GABA B receptor agonist

Neurology

Excessive sleepiness

Marketed

2,100

6

10/24

Eli Lilly

Adverum Biotechnologies

Ixo-vec

Gene therapy

Ophthalmology

wAMD

Phase 3

262

7

10/26

Novartis

Avidity Biosciences

-

AOC Platform

Neurology

DM1; FSHD; DMD

Phase 3

12,000